Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

bioAffinity Technologies (BIAF) Cost of Revenue: 2022-2025

Historic Cost of Revenue for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $942,211.

  • bioAffinity Technologies' Cost of Revenue fell 34.58% to $942,211 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 19.67%. This contributed to the annual value of $6.0 million for FY2024, which is 243.70% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Cost of Revenue of $942,211 as of Q3 2025, which was down 7.32% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Cost of Revenue ranged from a high of $1.7 million in Q4 2023 and a low of $87 during Q1 2023.
  • In the last 3 years, bioAffinity Technologies' Cost of Revenue had a median value of $1.4 million in 2025 and averaged $1.0 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 1,808,452.87% in 2024, then slumped by 34.58% in 2025.
  • bioAffinity Technologies' Cost of Revenue (Quarterly) stood at $175 in 2022, then surged by 951,248.00% to $1.7 million in 2023, then dropped by 6.17% to $1.6 million in 2024, then crashed by 34.58% to $942,211 in 2025.
  • Its Cost of Revenue was $942,211 in Q3 2025, compared to $1.0 million in Q2 2025 and $1.4 million in Q1 2025.